手机版 English 帮助中心
外文文献知网节
文献信息节点
基本信息 摘要 关键词 核心评价 相关文献
Journal | [J] 预防医学研究 Volume 4, Issue 7. 2022.
甲状腺髓样癌治疗的最新进展
作者 : 周 　庆, 吴 耀禄
DOI: 10.12361/2705-0459-04-07-93299
全部来源
获取全文
摘要 / Abstract
甲状腺髓样癌（MTC）是一种神经内分泌肿瘤，约占甲状腺恶性肿瘤的3%-5%，通常比分化型甲状腺癌更 具侵袭性。MTC虽然不常见，但其独特的特征与其他内分泌肿瘤有特殊关联。目前，手术切除仍然是治疗的主要手 段，尽管放疗和最新的靶向治疗已用于转移性疾病，然而辅助治疗的研究仍然有限。因此，本综述总结了MTC管理 的最新证据和指南，对该疾病的治疗提供更新的理论依据。
关键词 / Keywords
甲状腺髓样癌；治疗
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
  • [1]Wells SA Jr, Asa SL, Dralle H, et al. Revised
  • American Thyroid Association guidelines for the management
  • of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610.
  • [2]Hadoux J, Pacini F, Tuttle RM, Schlumberger M.
  • Management of advanced medullary thyroid cancer. Lancet
  • Diabetes Endocrinol. 2016 Jan;4(1):64-71.
  • [3]Elisei R, Cosci B, Romei C, et al. Prognostic
  • significance of somatic RET oncogene mutations in sporadic
  • medullary thyroid cancer: a 10-year follow-up study. J Clin
  • Endocrinol Metab. 2008;93(3):682-687.
  • [4]Mulligan LM, Kwok JB, Healey CS, et al. Germ-line
  • mutations of the RET proto-oncogene in multiple endocrine
  • neoplasia type 2A. Nature. 1993;363(6428):458-460.
  • [5]Marsh DJ, Learoyd DL, Andrew SD, et al. Somatic
  • mutations in the RET proto-oncogene in sporadic medullary
  • thyroid carcinoma. Clin Endocrinol (Oxf). 1996;44(3):249-257.
  • [6]Agrawal N, Jiao Y, Sausen M, et al. Exomic sequencing
  • of medullary thyroid cancer reveals dominant and mutually
  • exclusive oncogenic mutations in RET and RAS. J Clin
  • Endocrinol Metab. 2013;98(2):E364-E369.
  • [7]Moura MM, Cavaco BM, Pinto AE, Leite V. High
  • prevalence of RAS mutations in RET-negative sporadic
  • medullary thyroid carcinomas. J Clin Endocrinol Metab.
  • 2011;96(5):E863-E868.
  • [8]Boichard A, Croux L, Al Ghuzlan A, et al. Somatic
  • RAS mutations occur in a large proportion of sporadic
  • RET-negative medullary thyroid carcinomas and extend to
  • a previously unidentified exon. J Clin Endocrinol Metab.
  • 2012;97(10):E2031-E2035.
  • [9]Machens A, Dralle H. Biomarker-based risk
  • stratification for previously untreated medullary thyroid cancer.
  • J Clin Endocrinol Metab. 2010;95(6):2655-2663.
  • [10]Konstantinidis A, Stang M, Roman SA, Sosa JA.
  • Surgical management of medullary thyroid carcinoma. Updates
  • Surg. 2017;69(2):151-160.
  • [11]Wells SA Jr, Asa SL, Dralle H, et al. Revised
  • American Thyroid Association guidelines for the management
  • of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610.
  • [12]Wells SA Jr, Robinson BG, Gagel RF, et al.
  • Vandetanib in patients with locally advanced or metastatic
  • medullary thyroid cancer: a randomized, double-blind phase
  • III trial [published correction appears in J Clin Oncol. 2013
  • Aug 20;31(24):3049]. J Clin Oncol. 2012;30(2):134-141.
  • [13]Elisei R, Schlumberger MJ, Müller SP, et al.
  • Cabozantinib in progressive medullary thyroid cancer
  • [published correction appears in J Clin Oncol. 2014 Jun
  • 10;32(17):1864]. J Clin Oncol. 2013;31(29):3639-3646.
  • [14]Schlumberger M, Elisei R, Müller S, et al. Overall
  • survival analysis of EXAM, a phase III trial of cabozantinib in
  • patients with radiographically progressive medullary thyroid
  • carcinoma. Ann Oncol. 2017;28(11):2813-2819.
  • [15]Hińcza-Nowak K, Kowalik A, Walczyk A, et al.
  • Immune Profiling of Medullary Thyroid Cancer-An Opportunity
  • for Immunotherapy. Genes (Basel). 2021;12(10):1534.
  • Published 2021 Sep 28.
  • [16]Jayasinghe R, Basnayake O, Jayarajah U, Seneviratne
  • S. Management of medullary carcinoma of the thyroid: a review.
  • J Int Med Res. 2022;50(7):3000605221110698.
  • [17]Dash A, Chakraborty S, Pillai MR, Knapp FF Jr.
  • Peptide receptor radionuclide therapy: an overview. Cancer
  • Biother Radiopharm. 2015;30(2):47-71.
  • [18]Gubbi S, Koch CA, Klubo-Gwiezdzinska J. Peptide
  • Receptor Radionuclide Therapy in Thyroid Cancer. Front
  • Endocrinol (Lausanne). 2022;13:896287. Published 2022 May
  • 30.
  • [19]Rowell NP. The role of external beam radiotherapy
  • in the management of medullary carcinoma of the thyroid: A
  • systematic review. Radiother Oncol. 2019;136:113-120.
《中国学术期刊(光盘版)》电子杂志社有限公司 KDN平台基础技术由KBASE 11.0提供
© 2014-2018中国知网(CNKI) 京公网安备11010802020460号 经营性网站备案信息 互联网出版许可证 新出网证(京)字271号 京ICP证040431号